Trends and clinical profile of leprosy cases in children and adolescents under 15 years old in inland Bahia, Brazil
DOI:
https://doi.org/10.21527/2176-7114.2025.50.15390Keywords:
adolescent health, child, epidemiology, health profile, leprosyAbstract
Leprosy remains a significant public health challenge in Brazil, and its transmission among children and adolescents under 15 years old is predominantly associated with household contacts. Monitoring the leprosy cases within this specific age group serves as a crucial indicator for disease surveillance and control efforts. Thus, the aim of this study was to describe the trend and clinical profile of leprosy in children and adolescents under 15 years old in inland Bahia, Brazil. This retrospective cross-sectional follow-up study was performed in a specialized reference center in the Paulo Afonso municipality, Bahia. The data were obtained from the records of leprosy patients under 15 years, treated and followed up by the service between 2008 and 2022. The mean new case detection rate of leprosy in children and adolescents at 13.6 (95% CI: 7.9–19.4) cases per 100,000. The highest frequency was in the 10- to 14-year-old age group, comprising 62.1% of cases. Contact screening identified 31.0% of cases, and 12.3% had some disability at diagnosis. Paucibacillary cases (77.6%) were more prevalent than multibacillary, with tuberculoid clinical form (56.9%). The cure rate was 96.4%. The study highlights the need to intensify epidemiological surveillance efforts, including actively searching for cases, particularly among individuals aged 10 to 14 years, who represent the highest proportion of leprosy cases. Targeted interventions and education campaigns tailored to this age group are imperative to enhance awareness, early detection, and access to care, ultimately mitigating the burden of leprosy and preventing long-term sequelae among children and adolescents.
References
1 Sugawara-Mikami M, et al. Pathogenicity and virulence of Mycobacterium leprae. Virulence. 2022;13(1):1985-2011. DOI: 10.1080/21505594.2022.2141987
2 Han XY, et al. A new Mycobacterium species causing diffuse lepromatous leprosy. Am J Clin Pathol. 2008;130(6):856-864. DOI: 10.1309/AJCPP72FJZZRRVMM
3 World Health Organization. Global Leprosy (Hansen Disease) Update, 2021: Moving towards Interruption of Transmission. 2022:429-450. [internet]. Available from: https://www.who.int/publications/i/item/who-wer9736-429-450. Accessed May 13, 2023.
4 World Health Organization. Global Leprosy (Hansen Disease) Update, 2020: Impact of COVID-19 on the Global Leprosy Control. 2021:421-444. [internet]. Available from: https://www.who.int/publications/i/item/who-wer9636-421-444. Accessed May 13, 2023.
5 World Health Organization. Towards Zero Leprosy. Global Leprosy (Hansen’s Disease) Strategy 2021–2030. World Health Organization; 2021. [internet]. Available from: https://apps.who.int/iris/handle/10665/340774. Accessed May 19, 2023.
6 Santos SD, Penna GO, Costa M da CN, Natividade MS, Teixeira MG. Leprosy in children and adolescents under 15 years old in an urban centre in Brazil. Mem Inst Oswaldo Cruz. 2016;111:359-364. DOI: 10.1590/0074-02760160002
7 Souza CDF de, Luna CF, Magalhães M de AFM. Leprosy transmission in Bahia, 2001-2015: modeling based on Joinpoint regression and spatial scan statistics. Epidemiologia e Serviços de Saúde. 2019;28(1)1-11. DOI: 10.5123/s1679-49742019000100015
8 Moraes PC de, Eidt LM, Koehler A, Pagani DM, Scroferneker ML. Epidemiological characteristics and trends of leprosy in children and adolescents under 15 years old in a low-endemic State in Southern Brazil. Rev Inst Med trop S Paulo. 2021;63:e80. DOI: 10.1590/S1678-9946202163080
9 Narang T, Kumar B. Leprosy in Children. Indian Journal of Paediatric Dermatology. 2019;20(1):12-24. DOI: 10.4103/ijpd.IJPD_108_18
10 Instituto Brasileiro de Geografia e Estatística. 2020. [internet]. Available from: https://sidra.ibge.gov.br/Tabela/1378#resultado. Accessed May 19, 2023.
11 Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde, Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis. Protocolo Clínico e Diretrizes Terapêuticas da Hanseníase. Brasília: Ministério da Saúde, 2022. Available from: https://www.gov.br/saude/pt-br/assuntos/saude-de-a-a-z/h/hanseniase/publicacoes/protocolo-clinico-e-diretrizes-terapeuticas-da-hanseniase-2022/view. Accessed May 19, 2023.
12 Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância das Doenças Transmissíveis. Diretrizes para vigilância, atenção e eliminação da Hanseníase como problema de saúde pública: manual técnico-operacional. Brasília: Ministério da Saúde, 2016. [Internet]. Available from: https://portalarquivos2.saude.gov.br/images/pdf/2016/fevereiro/04/diretrizes-eliminacao-hanseniase-4fev16-web.pdf. Accessed May 19, 2023.
13 Lima IF de, Braga IO, Melo IF de SAA de, Nery JS, Takenami IO, Tenório PP. Hanseníase em uma região semiárida da Bahia: uma análise de 2001 a 2017. Revista de Medicina. 2023;102(2):e-201518. DOI: 10.11606/issn.1679-9836.v102i2e-201518
14 Silva VS da, Braga IO, Palácio MAV, Takenami I. Cenário epidemiológico da hanseníase e diferenças por sexo. Revista da Sociedade Brasileira de Clínica Médica. 2021;19(2):74-81.
15 Brasil. Ministério da Saúde. Boletim Epidemiológico de Hanseníase. Número Especial. Brasília. Ministério da Saúde, 2023. [Internet]. Available from: https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/boletins/epidemiologicos/especiais/2022/boletim-epidemiologico-de-hanseniase-_-25-01-2022.pdf/view. Accessed May 19, 2023.
16 Ribeiro SLE, et al. Epidemiological, clinical and immune factors that influence the persistence of antiphospholipid antibodies in leprosy. Advances in Rheumatology. 2019;59(52). DOI: 10.1186/s42358-019-0094-4
17 Monteiro LD, Mello FRM, Miranda TP, Heukelbach J. Hanseníase em menores de 15 anos no estado do Tocantins, Brasil, 2001-2012: padrão epidemiológico e tendência temporal. Rev Bras Epidemiol. 2019;22:e190047. DOI: 10.1590/1980-549720190047
18 Gama MEF, Pereira APC. Trend of pediatric leprosy in an endemic area in Northeast of Brazil, 2008-2018. Enferm Infecc Microbiol Clin. 2023;S2529-993X(23)00254-X. DOI: 10.1016/j.eimce.2023.06.009
19 Sales BN, Sousa GO, Machado RS, Rocha GM de M, Oliveira GAL de. Caracterização epidemiológica da hanseníase nas regiões Norte e Nordeste do Brasil. Research, Society and Development. 2020;9(8):e894986313-e894986313. DOI: 10.33448/rsd-v9i8.6313
20 Martoreli Júnior JF, et al. Clusters of risk for the occurrence of leprosy and disabilities in children under 15 years of age in Cuiabá: a geospatial study. Rev Bras Epidemiol. 2023;26:e230006. DOI: 10.1590/1980-549720230006
21 Azevedo YP, et al. Perfil epidemiológico e distribuição espacial da hanseníase em Paulo Afonso, Bahia. Rev Baiana Enferm. 2021;35:e37805. DOI: 10.18471/rbe.v35.37805
22 Vieira MCA, Nery JS, Paixão ES, Andrade KVF de, Penna GO, Teixeira MG. Leprosy in children under 15 years of age in Brazil: A systematic review of the literature. PLOS Neglected Tropical Diseases. 2018;12(10):e0006788. DOI: 10.1371/journal.pntd.0006788
23 Brito KKG, Andrade SS da C, Diniz IV, Matos SDO, Oliveira SH dos S, Oliveira MJGO. Caracterização dos casos de hanseníase diagnosticados através do exame de contato. Revenferm UFPE online. 2016:10(2):435-441. DOI: 10.5205/reuol.8557-74661-1-SM1002201608
24 Sousa CRS de, Feitosa MC da R, Pinheiro ABF, Cavalcante KKS. Aspectos epidemiológicos da hanseníase em um município nordestino do Brasil. Rev Bras Promoc Saúde. 2019;32:1-10. DOI: 10.5020/18061230.2019.9469
25 Sarode G, et al. Epidemiological aspects of leprosy. Dis Mon. 2020;66(7):100899. DOI: 10.1016/j.disamonth.2019.100899
26 Freitas BHBM de, Cortela D da CB, Ferreira SMB. Tendência da hanseníase em menores de 15 anos em Mato Grosso (Brasil), 2001-2013. Rev Saúde Pública. 2017;51:28. DOI: 10.1590/S1518-8787.2017051006884
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Context and Health Journal
This work is licensed under a Creative Commons Attribution 4.0 International License.
By publishing in Revista Contexto & Saúde, authors agree to the following terms:
The works are licensed under the Creative Commons Atribuição 4.0 Internacional (CC BY 4.0) license, which allows:
Share — to copy and redistribute the material in any medium or format;
Adapt — to remix, transform, and build upon the material for any purpose, including commercial.
These permissions are irrevocable, provided that the following terms are respected:
Attribution — authors must be properly credited, with a link to the license and indication of any changes made.
No additional restrictions — no legal or technological measures may be applied that restrict the use permitted by the license.
Notes:
The license does not apply to elements in the public domain or covered by legal exceptions.
The license does not grant all rights necessary for specific uses (e.g., image rights, privacy, or moral rights).
The journal is not responsible for opinions expressed in the articles, which are the sole responsibility of the authors. The Editor, with the support of the Editorial Board, reserves the right to suggest or request modifications when necessary.
Only original scientific articles presenting research results of interest that have not been published or simultaneously submitted to another journal with the same objective will be accepted.
Mentions of trademarks or specific products are intended solely for identification purposes, without any promotional association by the authors or the journal.
License Agreement (for articles published from September 2025): Authors retain copyright over their article and grant Revista Contexto & Saúde the right of first publication.
